FrancophonIA/ELRC3.0 huggingface dataset:
English: Eporatio 1,000 IU/0.5 ml injection Epoetin theta
Croatian: Eporatio 1000 IU/0,5 ml injekcija epoetin theta s.c. i.v.
English: Eporatio 3,000 IU/0.5 ml injection Epoetin theta
Croatian: Eporatio 3000 IU/0,5 ml injekcija epoetin theta s.c. i.v.
English: Eporatio 1,000 IU/0.5 ml solution for injection in pre-filled syringe 2 years
Croatian: Eporatio 1000 IU/0,5 ml otopina za injekciju u napunjenoj štrcaljki 2 godine
English: Eporatio 1,000 IU/0.5 ml solution for injection in pre-filled syringe Epoetin theta
Croatian: Eporatio 1000 IU/0,5 ml otopina za injekciju u napunjenoj štrcaljki epoetin theta
English: Eporatio 20,000 IU/1 ml solution for injection in pre-filled syringe
Croatian: Eporatio 20 000 IU/1 ml otopina za injekciju u napunjenoj štrcaljki
English: EU/1/09/573/004 6 pre-filled syringes with safety device EU/1/09/573/030 6 pre-filled syringes with safety needle
Croatian: EU/1/09/573/003 6 napunjenih štrcaljki EU/1/09/573/004 6 napunjenih štrcaljki sa sigurnosnom napravom EU/1/09/573/030 6 napunjenih štrcaljki sa sigurnosnom iglom
English: Eporatio 10,000 IU/1 ml solution for injection in pre-filled syringe Epoetin theta
Croatian: Eporatio 10 000 IU/1 ml otopina za injekciju u napunjenoj štrcaljki epoetin theta
English: Eporatio 10,000 IU/1 ml solution for injection in pre-filled syringe
Croatian: Eporatio 10 000 IU/1 ml otopina za injekciju u napunjenoj štrcaljki
English: Eporatio 4,000 IU/0.5 ml solution for injection in pre-filled syringe EU/1/09/573/007
Croatian: Eporatio 4000 IU/0,5 ml otopina za injekciju u napunjenoj štrcaljki EU/1/09/573/007
English: Eporatio 5,000 IU/0.5 ml solution for injection in pre-filled syringe Epoetin theta
Croatian: Eporatio 5000 IU/0,5 ml otopina za injekciju u napunjenoj štrcaljki epoetin theta
English: Eporatio 5,000 IU/0.5 ml solution for injection in pre-filled syringe EU/1/09/573/009
Croatian: Eporatio 5000 IU/0,5 ml otopina za injekciju u napunjenoj štrcaljki EU/1/09/573/009
English: Eporatio 30,000 IU/1 ml solution for injection in pre-filled syringe
Croatian: Eporatio 30 000 IU/1 ml otopina za injekciju u napunjenoj štrcaljki
English: Eporatio 2,000 IU/0.5 ml solution for injection in pre-filled syringe Epoetin theta
Croatian: Eporatio 2000 IU/0,5 ml otopina za injekciju u napunjenoj štrcaljki epoetin theta
English: Eporatio 4,000 IU/0.5 ml solution for injection in pre-filled syringe Epoetin theta
Croatian: Eporatio 4000 IU/0,5 ml otopina za injekciju u napunjenoj štrcaljki epoetin theta
English: Eporatio 4,000 IU/0.5 ml solution for injection in pre-filled syringe 2 years
Croatian: Eporatio 4000 IU/0,5 ml otopina za injekciju u napunjenoj štrcaljki 2 godine
English: EU/1/09/573/008 6 pre-filled syringes with safety device EU/1/09/573/032 6 pre-filled syringes with safety needle
Croatian: EU/1/09/573/007 6 napunjenih štrcaljki EU/1/09/573/008 6 napunjenih štrcaljki sa sigurnosnom napravom EU/1/09/573/032 6 napunjenih štrcaljki sa sigurnosnom iglom
English: Eporatio 2,000 IU/0.5 ml injection Epoetin theta
Croatian: Eporatio 2000 IU/0,5 ml injekcija epoetin theta s.c. i.v.
English: EU/1/09/573/006 6 pre-filled syringes with safety device EU/1/09/573/031 6 pre-filled syringes with safety needle
Croatian: EU/1/09/573/005 6 napunjenih štrcaljki EU/1/09/573/006 6 napunjenih štrcaljki sa sigurnosnom napravom EU/1/09/573/031 6 napunjenih štrcaljki sa sigurnosnom iglom
English: Eporatio 2,000 IU/0.5 ml solution for injection in pre-filled syringe 2 years
Croatian: Eporatio 2000 IU/0,5 ml otopina za injekciju u napunjenoj štrcaljki 2 godine
English: EU/1/09/573/010 6 pre-filled syringes with safety device EU/1/09/573/033 6 pre-filled syringes with safety needle
Croatian: EU/1/09/573/009 6 napunjenih štrcaljki EU/1/09/573/010 6 napunjenih štrcaljki sa sigurnosnom napravom EU/1/09/573/033 6 napunjenih štrcaljki sa sigurnosnom iglom
English: Eporatio 3,000 IU/0.5 ml solution for injection in pre-filled syringe EU/1/09/573/005
Croatian: Eporatio 3000 IU/0,5 ml otopina za injekciju u napunjenoj štrcaljki EU/1/09/573/005
English: Eporatio 3,000 IU/0.5 ml solution for injection in pre-filled syringe Epoetin theta
Croatian: Eporatio 3000 IU/0,5 ml otopina za injekciju u napunjenoj štrcaljki epoetin theta
English: Eporatio 1,000 IU/0.5 ml solution for injection in pre-filled syringe EU/1/09/573/001
Croatian: Eporatio 1000 IU/0,5 ml otopina za injekciju u napunjenoj štrcaljki EU/1/09/573/001
English: Eporatio 3,000 IU/0.5 ml solution for injection in pre-filled syringe 2 years
Croatian: Eporatio 3000 IU/0,5 ml otopina za injekciju u napunjenoj štrcaljki 2 godine
English: EU/1/09/573/002 6 pre-filled syringes with safety device EU/1/09/573/029 6 pre-filled syringes with safety needle
Croatian: EU/1/09/573/001 6 napunjenih štrcaljki EU/1/09/573/002 6 napunjenih štrcaljki sa sigurnosnom napravom EU/1/09/573/029 6 napunjenih štrcaljki sa sigurnosnom iglom.
English: Common in patients with chronic renal failure (may affect up to 1 in 10 people) - Blood clot in the arterio-venous fistula in patients on dialysis.
Croatian: Često u bolesnika s kroničnim zatajenjem bubrega (mogu se javiti u do 1 na 10 osoba)
English: Further information on Exjade can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Croatian: Više informacija o lijeku Exjade možete naći na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Exjade is taken once a day at around the same time.
Croatian: Lijek Exjade uzima se jedanput dnevno u otprilike isto doba svakoga dana.
English: Exjade (deferasirox)
Croatian: Exjade (deferasiroks)
English: About half of the patients were under the age of 16 years, and 56 were less than 6 years old.
Croatian: Otprilike polovica bolesnika imala je manje od 16 godina, dok je 56 bolesnika imalo manje od 6 godina.
English: Exjade was not as effective overall as the comparator medicine.
Croatian: Lijek Exjade nije u cijelosti bio jednako učinkovit kao usporedni lijek.
English: Treatment may need to be interrupted or stopped depending on the results of the tests.
Croatian: Možda će biti potrebno prekinuti ili obustaviti liječenje, ovisno o rezultatima pretraga.
English: What is Exjade and what is it used for?
Croatian: Što je Exjade i za što se koristi?
English: It must not be used in combination with other iron chelators.
Croatian: Ne smije se primjenjivati u kombinaciji s drugim kelatorima željeza.
English: Exjade received a marketing authorisation valid throughout the EU on 28 August 2006.
Croatian: Lijek Exjade dobio je odobrenje za stavljanje u promet koje je na snazi u EU-u od 28. kolovoza 2006.
English: What measures are being taken to ensure the safe and effective use of Exjade?
Croatian: Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Exjade?
English: The company that markets Exjade must issue an education pack to healthcare professionals.
Croatian: Tvrtka koja proizvodi lijek Exjade mora objaviti edukacijski paket za zdravstvene radnike.
English: Other information about Exjade
Croatian: Ostale informacije o lijeku Exjade
English: The main measure of effectiveness was the change in iron levels in the liver after 12 months of treatment.
Croatian: Glavna mjera učinkovitosti bila je promjena razina željeza u jetri nakon 12 mjeseci liječenja.
English: In more than half of these patients the iron level was reduced satisfactorily after a year of treatment with Exjade, including patients aged between 2 and 5 years.
Croatian: U više od polovice tih bolesnika razina željeza zadovoljavajuće je smanjena nakon jedne godine liječenja lijekom Exjade, uključujući bolesnike u dobi od 2 do 5 godina.
English: Exjade is a medicine used to treat chronic iron overload (an excess of iron in the body) in:
Croatian: Exjade je lijek koji se koristi za liječenje kroničnog preopterećenja željezom (prevelike količine željeza u tijelu) u:
English: However, in the 381 patients who had particularly high levels of iron at the beginning of the study and who received comparable amounts of Exjade and deferoxamine, the two medicines were as effective as each other.
Croatian: Međutim, u 381 bolesnika koji su imali osobito visoke razine željeza na početku ispitivanja i koji su primili usporedive količine lijeka Exjade i deferoksamina, oba ta lijeka bila su jednako djelotvorna.
English: Side effects reported with Exjade are carefully evaluated and any necessary action taken to protect patients.
Croatian: Nuspojave prijavljene za lijek Exjade pažljivo se procjenjuju i poduzimaju se potrebne mjere za zaštitu bolesnika.
English: The body cannot remove iron effectively and excess iron can cause damage.
Croatian: Tijelo ne može učinkovito ukloniti željezo te višak željeza može uzrokovati oštećenja.
English: As for all medicines, data on the use of Exjade are continuously monitored.
Croatian: Kao i za sve lijekove, podatci o primjeni lijeka Exjade kontinuirano se prate.
English: What are the risks associated with Exjade?
Croatian: Koji su rizici povezani s lijekom Exjade?
English: Exjade must not be used in people whose creatinine clearance is less than 60 ml per minute.
Croatian: Lijek Exjade ne smiju uzimati ljudi koji imaju klirens kreatinina manji od 60 ml/min.
English: Effectiveness was determined by the level of iron in the liver before and after one year of treatment.
Croatian: Učinkovitost se utvrđivala na osnovi razine željeza u jetri prije i nakon jedne godine liječenja.
English: For more information about using Exjade, see the package leaflet or contact your doctor or pharmacist.
Croatian: Za više informacija o primjeni lijeka Exjade pogledajte uputu o lijeku ili se obratite liječniku ili ljekarniku.
English: The European Medicines Agency decided that Exjade's benefits are greater than its risks and it can be authorised for use in the EU.
Croatian: Europska agencija za lijekove zaključila je da koristi od lijeka Exjade nadmašuju s njim povezane rizike te da lijek može biti odobren za primjenu u Europskoj uniji.
English: The dispersible tablets should be taken on an empty stomach (at least 30 minutes before food), and the film-coated tablets and granules can be taken on an empty stomach or with a light meal.
Croatian: Tablete za oralnu suspenziju uzimaju se na prazan želudac (najmanje 30 minuta prije obroka), a tablete obložene filmom i granule mogu se uzimati na prazan želudac ili uz lagani obrok.
English: Why is Exjade authorised in the EU?
Croatian: Zašto je lijek Exjade odobren u EU-u?
English: The granules are sprinkled on soft food such as yogurt or apple sauce that the patient can eat.
Croatian: Granule treba posipati na meku hranu, npr. jogurt ili jabučnu kašu, koju bolesnik može pojesti.
English: The iron level was reduced satisfactorily in 53% of the patients receiving Exjade, compared with 66% of the patients receiving deferoxamine.
Croatian: Razina željeza zadovoljavajuće je smanjena u 53 % bolesnika koji su primali lijek Exjade, u usporedbi sa 66 % bolesnika koji su primali deferoksamin.
English: An overview of Exjade and why it is authorised in the EU
Croatian: Pregled informacija o lijeku Exjade i zašto je odobren u EU-u
English: The active substance in Exjade, deferasirox, is an ‘iron chelator'.
Croatian: Djelatna tvar u lijeku Exjade, deferasiroks, jest „kelator željeza”.
English: In a further main study involving 166 patients from 10 years of age (including 21 patients aged 10 to 18 years) with non-transfusion-dependent thalassaemia syndromes and iron overload, Exjade was more effective than placebo (a dummy treatment).
Croatian: U još jednom glavnom ispitivanju u kojem je sudjelovalo 166 bolesnika u dobi od 10 godina i starijih (uključujući 21 bolesnika u dobi od 10 do 18 godina) sa sindromima talasemije neovisnima o transfuziji i preopterećenjem željezom, lijek Exjade pokazao se učinkovitijim od placeba (prividno liječenje).
English: Other common side effects (in up to 1 patient in 10) include nausea (feeling sick), vomiting, diarrhoea, indigestion, abdominal (belly) pain, constipation, headache, rash, itching, blood tests showing raised transaminases (which may suggest liver damage) and protein in urine.
Croatian: Ostale česte nuspojave (u do 1 na 10 bolesnika) jesu mučnina (osjećaj slabosti), povraćanje, proljev, loša probava, abdominalna bol (bol u trbuhu), zatvor, glavobolja, osip, svrbež, povišene transaminaze zabilježene u krvnim pretragama (što može upućivati na oštećenje jetre) i bjelančevine u mokraći.
English: How is Exjade used?
Croatian: Kako se Exjade koristi?
English: The most common side effect with Exjade (which may affect more than 1 in 10 people) is increased blood creatinine (a marker of kidney problems).
Croatian: Najčešća nuspojava lijeka Exjade (koja se može javiti u više od 1 na 10 osoba) jest povišena razina kreatinina u krvi (marker problema s bubrezima).
English: Another study involved 184 patients who could not be treated with deferoxamine, including patients with beta thalassaemia major and with other types of anaemia.
Croatian: U drugom ispitivanju sudjelovalo je 184 bolesnika koji se nisu mogli liječiti deferoksaminom, uključujući bolesnike s beta-talasemijom major i drugim vrstama anemije.
English: In patients treated with Exjade, liver iron levels decreased on average by 3.8 mg per gram of liver compared with an average increase of 0.4 mg per gram of liver in patients treated with placebo.
Croatian: U bolesnika liječenih lijekom Exjade razine željeza u jetri u prosjeku su se smanjile za 3,8 mg po gramu jetre, dok su se u bolesnika liječenih placebom te razine povećale za prosječno 0,4 mg po gramu jetre.
English: The film-coated tablets are to be swallowed with water while the dispersible tablets are to be mixed with a liquid to make up a suspension that the patient can drink.
Croatian: Tablete obložene filmom treba progutati s vodom, a tablete za oralnu suspenziju trebaju se pomiješati s tekućinom radi pripreme suspenzije koju bolesnik može popiti.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Exjade have also been included in the summary of product characteristics and the package leaflet.
Croatian: Preporuke i mjere opreza kojih se zdravstveni radnici i bolesnici trebaju pridržavati u cilju sigurne i učinkovite primjene lijeka Eliquis nalaze se također u sažetku opisa svojstava lijeka i u uputi o lijeku.
English: Exjade can only be obtained with a prescription and treatment should be started and supervised by a doctor who is experienced in the treatment of chronic iron overload.
Croatian: Lijek Exjade izdaje se samo na liječnički recept, a liječenje mora započeti i nadzirati liječnik s iskustvom u liječenju kroničnog preopterećenja željezom.
English: In chronic iron overload due to blood transfusions, one main study compared Exjade with deferoxamine in 591 patients with beta thalassaemia major.
Croatian: U bolesnika s kroničnim preopterećenjem željezom zbog transfuzija krvi lijek Exjade uspoređivan je s deferoksaminom u okviru jednog glavnog ispitivanja na 591 bolesniku s beta-talasemijom major.
English: The starting dose of Exjade depends on the patient's body weight, on which form of the medicine is being taken, what the medicine is used for, and on the level of iron overload.
Croatian: Početna doza lijeka Exjade ovisi o tjelesnoj težini bolesnika, obliku lijeka koji se primjenjuje, razlogu za liječenje i razini preopterećenja željezom.
English: The company will also perform the following studies: a study on the long-term effects of the filmcoated tablets and dispersible tablets in children aged over 10 years with non-transfusion-dependent thalassaemia; and a study to assess the safety of the film-coated tablets (particularly when they are crushed) in children.
Croatian: Osim toga, tvrtka će provesti sljedeća ispitivanja: ispitivanje o dugoročnim koristima tableta obloženih filmom i tableta za oralnu suspenziju na djeci starijoj od 10 godina s talasemijom neovisnom o transfuziji te ispitivanje u okviru kojeg bi se ocjenjivala sigurnost tableta obloženih filmom u djece (osobito kada su zdrobljene).
English: This pack aims to inform them about the treatment recommendations with Exjade, including choosing the right dose, that the doses are different for dispersible tablets compared to film-coated tablets or granules, and the need to monitor the patient's health, especially kidney function.
Croatian: Svrha tog paketa jest obavijestiti zdravstvene radnike o preporukama za liječenja lijekom Exjade, uključujući odabir prave doze, o razlikovanju doze ovisno o tome uzima li bolesnik tablete za oralnu suspenziju ili tablete obložene filmom ili granule te o tome da je potrebno nadzirati bolesnikovo zdravstveno stanje, osobito funkciju rada bubrega.
English: Cases of metabolic acidosis (when the body produces more acid than it gets rid of) have been reported with Exjade, mostly in patients with kidney impairment.
Croatian: Pri uporabi lijeka Exjade zabilježeni su slučajevi metaboličke acidoze (stanja u kojem tijelo proizvodi više kiseline nego što je izlučuje), većinom u bolesnika s oštećenjem bubrega.
English: How does Exjade work?
Croatian: Kako djeluje Exjade?
English: Kidney and liver tests should be done before starting treatment and at regular intervals during treatment with Exjade.
Croatian: Pretrage funkcija bubrega i jetre treba provoditi prije početka liječenja i u redovitim vremenskim razmacima tijekom uzimanja lijeka Exjade.
English: What benefits of Exjade have been shown in studies?
Croatian: Koje su koristi od lijeka Exjade utvrđene u ispitivanjima?
English: Exjade contains the active substance deferasirox.
Croatian: Lijek Exjade sadržava djelatnu tvar deferasiroks.
English: • patients from 6 years of age who have beta thalassaemia major (an inherited blood disorder in which patients do not have enough normal haemoglobin in the blood) and who receive frequent blood transfusions;
Croatian: • bolesnika u dobi od 6 godina i starijih koji imaju beta-talasemiju major (nasljedni poremećaj krvi pri kojem bolesnici nemaju normalne vrijednosti hemoglobina u krvi) i koji često primaju transfuziju krvi;
English: It is available as film-coated tablets, dispersible tablets and granules.
Croatian: Lijek je dostupan u obliku tableta obloženih filmom, tableta za oralnu suspenziju te u obliku granula.
English: Interruption of treatment with Exjade should be considered in patients who develop this condition.
Croatian: U bolesnika kod kojih je nastalo to stanje trebalo bi razmotriti prekid liječenja lijekom Exjade.
English: Cases of kidney and liver failure have been reported with Exjade.
Croatian: Pri uporabi lijeka Exjade zabilježeni su slučajevi zatajenja bubrega i jetre.
English: For the full list of side effects of Exjade, see the package leaflet.
Croatian: Potpuni popis nuspojava zabilježenih pri primjeni lijeka Exjade potražite u uputi o lijeku.
English: Novantrone is marketed in the following EU member states: Cyprus, Finland, France, Germany, Greece, Italy, Romania, Slovenia, Spain and Sweden, as well as Iceland and Norway.
Croatian: Lijek Novantrone stavljen je u promet u sljedećim državama članicama EU-a: Cipru, Finskoj, Francuskoj, Njemačkoj, Grčkoj, Italiji, Rumunjskoj, Sloveniji, Španjolskoj, Švedskoj, kao i Islandu te Norveškoj.
English: What is Novantrone?
Croatian: Što je Novantrone?
English: It is also available in the EU under the trade names Elsep and Ralenova.
Croatian: U EU-u je također dostupan pod trgovačkim nazivima Elsep i Ralenova.
English: The European Commission issued a decision on this opinion on 24/06/2016.
Croatian: Europska komisija usvojila je odluku o ovom mišljenju 24. lipnja 2016.
English: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Croatian: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom24. lipnja 2016.
English: Daily doses vary from 6 to 14 mg per square metre of body surface area (calculated using the patient's height and weight).
Croatian: Dnevne doze mogu iznositi od 6 do 14 mg po kvadratnom metru tjelesne površine (izračunano na temelju visine i tjelesne težine bolesnika).
English: Why was Novantrone reviewed?
Croatian: Zašto je Novantrone ponovno ocjenjivan?
English: • Non-Hodgkin's lymphoma;
Croatian: • ne-Hodgkinova limfoma;
English: The company will prepare a survey for healthcare professionals to check how well these materials work.
Croatian: Tvrtka će pripremiti anketu za zdravstvene radnike kako bi provjerila korisnost tih materijala.
English: The Committee also harmonised other sections of the SmPC including sections 4.4 (special warnings and precautions for use), 4.5 (interactions), 4.6 (fertility, pregnancy and lactation), 4.7 (effects on ability to drive and use machines), 4.8 (side effects) and 5.1 (pharmacodynamic properties).
Croatian: Odbor je također uskladio druge odjeljke sažetka opisa svojstava lijeka, uključujući odjeljke 4.4. (posebna upozorenja i mjere opreza pri uporabi), 4.5. (interakcije s drugim lijekovima), 4.6. (plodnost, trudnoća i dojenje), 4.7. (utjecaj na sposobnost upravljanja vozilima i strojevima), 4.8. (nuspojave) i5.1. (farmakodinamička svojstva).
English: Novantrone has been authorised in the EU via national procedures.
Croatian: Lijek Novantrone odobren je u EU-u u okviru nacionalnih postupaka.
English: • Highly active relapsing multiple sclerosis associated with rapidly evolving disability, in patients for whom no alternative treatments are available.
Croatian: • visokoaktivne relapsne multiple skleroze povezane s brzim razvojem invaliditeta u bolesnika kojima nisu dostupni alternativni načini liječenja.
English: The company that markets these medicines is MEDA.
Croatian: Te lijekove stavlja u promet tvrtka MEDA.
English: Patients will receive a guide to the risks and an alert card describing the signs and symptoms to watch out for.
Croatian: Bolesnici će dobiti smjernice o riziku i karticu s upozorenjima s opisom znakova i simptoma na koje je potrebno pripaziti.
English: The recommended dose of Novantrone and the duration of treatment depend on the disease it is used for, whether it is used in combination with other medicines, on the height and weight of the patient, and on the response to treatment.
Croatian: Preporučena doza lijeka Novantrone i trajanje liječenja ovise o bolesti za koju se upotrebljava, o tome upotrebljava li se u kombinaciji s drugim lijekovima, visini i tjelesnoj težini bolesnika i odgovoru na liječenje.
English: Additionally, Novantrone must not be used for the treatment of multiple sclerosis in pregnant women.
Croatian: Nadalje, lijek Novantrone ne smije se upotrebljavati za liječenje multiple skleroze u trudnica.
English: The educational materials will include a guide and checklist for healthcare professionals informing of the risks of cardiotoxicity (harm to the heart) and leukaemia with the medicine, and how patients should be monitored.
Croatian: Edukativni će materijali uključivati smjernice i kontrolni popis za zdravstvene radnike s informacijama o rizicima od kardiotoksičnosti (oštećenja srca) i leukemije povezanih s lijekom te o načinu na koji je potrebno nadzirati bolesnike.
English: As part of this plan, the company will provide educational materials about the use of Novantrone in patients with multiple sclerosis.
Croatian: Tvrtka će u okviru toga plana pružiti edukativne materijale o uporabi lijeka Novantrone u bolesnika s multiplom sklerozom.
English: A risk management plan will be developed to ensure that Novantrone is used as safely as possible.
Croatian: Pripremit će se plan upravljanja rizikom kako bi se osigurala što sigurnija primjena lijeka Novantrone.
English: • Metastatic breast cancer (breast cancer that has spread to other parts of the body);
Croatian: • metastatskog raka dojke (raka dojke koji se proširio u druge dijelove tijela);
English: It is also used to treat patients with worsening multiple sclerosis when no alternative treatments are available.
Croatian: Također se primjenjuje za liječenje bolesnika s multiplom sklerozom koja se pogoršava ako nisu dostupni alternativni načini liječenja.